Effect of BMS-582949 treatment on gene expression in osteoclasts

ABSTRACT: Controlling excessive osteoclastic activity is a promising strategy for many bone disease treatments. Here we report that 10 μM BMS-582949, a clinical p38α inhibitor,dromatically suppresses the osteoclast differentiation in vitro. Our results provide a evidence that BMS-582949 could be a candicdate drug for the therapy of osteolytic diseases.

ORGANISM(S): Mus musculus

PROVIDER: GSE249860 | GEO | 2024/02/29

REPOSITORIES: GEO